Relypsa announced the initiation of patient enrollment in its PEARL-HF study, a Phase 2b trial of the company’s lead compound, RLY5016 for the prevention of hyperkalemia in heart failure patients. This multi-center, international, randomized, placebo-controlled study is designed to assess the efficacy, safety and tolerability of RLY5016.
RLY5016 is a novel, non-absorbed, potassium binder designed for chronic use. It is being evaluated for the prevention and treatment of hyperkalemia in heart failure patients, especially those patients with underlying chronic kidney disease treated with Renin-Angiotensin-Aldosterone-System (RAAS) inhibitors.
For more information call (408) 200-9500 or visit www.relypsa.com.